MCID: FML187
MIFTS: 38

Familial Hypertension malady

Categories: Rare diseases, Genetic diseases, Cardiovascular diseases, Blood diseases

Aliases & Classifications for Familial Hypertension

Aliases & Descriptions for Familial Hypertension:

Name: Familial Hypertension 50
Genetic Hypertension 69

Classifications:



Summaries for Familial Hypertension

MalaCards based summary : Familial Hypertension, also known as genetic hypertension, is related to pseudohypoaldosteronism, type iie and alzheimer disease-4. An important gene associated with Familial Hypertension is WNK4 (WNK Lysine Deficient Protein Kinase 4), and among its related pathways/superpathways are Renin secretion and Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics. The drugs Aspirin and Iron have been mentioned in the context of this disorder. Affiliated tissues include kidney, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cardiovascular system

Related Diseases for Familial Hypertension

Diseases in the Familial Hypertension family:

Hypertension, Essential Hypertension, Essential 7
Hypertension, Essential 8 Malignant Essential Hypertension
Malignant Hypertension Benign Essential Hypertension
Benign Secondary Hypertension Malignant Secondary Hypertension

Diseases related to Familial Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 41)
id Related Disease Score Top Affiliating Genes
1 pseudohypoaldosteronism, type iie 10.7
2 alzheimer disease-4 10.3 CUL3 KLHL3
3 thiamine metabolism dysfunction syndrome 2 10.2 CUL3 KLHL3 WNK4
4 cascade stomach 10.2 AGT AGTR1 REN
5 hyperuricemic nephropathy, familial juvenile 2 10.2 AGT AGTR1 REN
6 flat umbilicus familial 10.2 AGT AGTR1 REN
7 malignant biphasic mesothelioma 10.1 KLHL3 REN WNK1 WNK4
8 aplasia cutis congenita recessive 10.1 AGT AGTR1 CYP11B2 GRK4
9 smith-mccort dysplasia 2 10.0 NR3C2 REN
10 pulmonary sarcoidosis 10.0 CUL3 KLHL3 NR3C2 WNK1 WNK4
11 laryngostenosis 10.0 AGT AGTR1 CYP11B2 NR3C2
12 immune system organ benign neoplasm 10.0 CYP11B2 NR3C2 REN
13 cataract 21, multiple types 10.0 HSD11B2 NR3C2 REN
14 aorta angiosarcoma 9.9 HSD11B2 NR3C2 REN
15 cerebral convexity meningioma 9.9 AGT AGTR1 NPPA
16 lymphadenitis 9.9 AGTR1 NPPA REN
17 microphthalmia, isolated, with coloboma 7 9.9 CYP11B2 NR3C2 REN WNK1 WNK4
18 hypogonadism mitral valve prolapse mental retardation 9.9 CYP11B2 NPPA REN
19 iris disease 9.9 AGT AGTR1 NPPA REN
20 eastern equine encephalitis 9.9 AGT AGTR1 NPPA REN
21 dystonia 25 9.9 CUL3 KLHL3 NR3C2 REN WNK1 WNK4
22 merkel cell carcinoma 9.9 CYP11B2 HSD11B2 NR3C2 REN
23 esophagus squamous cell papilloma 9.9 CYP11B2 HSD11B2 NR3C2 REN
24 bronchiectasis with or without elevated sweat chloride 3 9.8 CYP11B2 HSD11B2 NR3C2 REN
25 prostate neuroendocrine neoplasm 9.8 AGT AGTR1 HSD11B2 NR3C2 REN
26 ceroid lipofuscinosis, neuronal, kufs type, adult onset 9.8 AGT NPPA REN
27 glioma susceptibility 1 9.8 CHGA CYP11B2 HSD11B2
28 hemorrhagic cystitis 9.8 AGTR1 NR3C2 REN
29 vestibular gland benign neoplasm 9.8 CHGA CYP11B2 REN
30 hypoaldosteronism, congenital, due to cmo i deficiency 9.8 AGT CYP11B2 HSD11B2 NR3C2 REN
31 panuveitis 9.6 AGTR1 CYP11B2 NPPA NR3C2 REN
32 clear cell adenocarcinoma 9.6 AGTR1 CYP11B2 NPPA NR3C2 REN
33 critical limb ischemia 9.6 AGTR1 CYP11B2 NPPA NR3C2 REN
34 xanthogranulomatous pyelonephritis 9.6 AGTR1 BMPR2 NPPA NR3C2 REN
35 myocardial infarction 9.3
36 hypertension and brachydactyly syndrome 9.3
37 pseudohypoaldosteronism 9.3
38 brachydactyly 9.3
39 iridocyclitis 9.3
40 hypertension, essential 9.1 AGT AGTR1 CYP11B2 GRK4 HSD11B2 NPPA
41 familial nasal acilia 7.8 AGT AGTR1 BMPR2 CAND1 CHGA COPS8

Graphical network of the top 20 diseases related to Familial Hypertension:



Diseases related to Familial Hypertension

Symptoms & Phenotypes for Familial Hypertension

GenomeRNAi Phenotypes related to Familial Hypertension according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.7 PDE3A
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.7 AGTR1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.7 PDE3A AGTR1 CHGA NR3C2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.7 AGTR1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.7 CHGA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.7 CHGA NR3C2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.7 AGTR1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-182 9.7 CHGA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.7 NR3C2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.7 NR3C2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.7 NR3C2 AGTR1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.7 NR3C2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-215 9.7 CHGA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.7 AGTR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.7 AGTR1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.7 CHGA NR3C2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.7 AGTR1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-97 9.7 NR3C2
19 Increased cell death HMECs cells GR00103-A-0 9.61 CAND1 COPS8 CUL3 KLHL3 NR3C2 RBX1

MGI Mouse Phenotypes related to Familial Hypertension:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.28 AGT AGTR1 BMPR2 CHGA CUL3 CYP11B2
2 growth/size/body region MP:0005378 10.15 CYP11B2 AGT AGTR1 BMPR2 CHGA COPS8
3 homeostasis/metabolism MP:0005376 10.1 AGT AGTR1 BMPR2 CHGA CUL3 CYP11B2
4 hematopoietic system MP:0005397 10.02 AGTR1 BMPR2 COPS8 CYP11B2 DRD1 KLHL3
5 mortality/aging MP:0010768 9.93 AGT AGTR1 BMPR2 CHGA COPS8 CUL3
6 muscle MP:0005369 9.61 BMPR2 CUL3 DRD1 HSD11B2 NPPA NR3C2
7 renal/urinary system MP:0005367 9.36 AGT AGTR1 BMPR2 CHGA CYP11B2 HSD11B2

Drugs & Therapeutics for Familial Hypertension

Drugs for Familial Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 390)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
2
Iron Approved Phase 4,Phase 2 7439-89-6 23925
3
Spironolactone Approved Phase 4,Phase 1,Phase 2,Early Phase 1 1952-01-7, 52-01-7 5833
4
Metoprolol Approved, Investigational Phase 4,Phase 3 37350-58-6, 51384-51-1 4171
5
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
6
Iloprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 78919-13-8 6443959
7
Bosentan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147536-97-8 104865
8
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 171596-29-5 110635
9
Treprostinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 81846-19-7 54786 6918140
10
Epoprostenol Approved Phase 4,Phase 3,Phase 2 61849-14-7, 35121-78-9 5280427 5282411
11
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
12
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
13
Ibuprofen Approved Phase 4 15687-27-1 3672
14
Nifedipine Approved Phase 4 21829-25-4 4485
15
Lisinopril Approved, Investigational Phase 4,Phase 2,Phase 1 83915-83-7 5362119
16
Losartan Approved Phase 4,Phase 2,Phase 3,Early Phase 1 114798-26-4 3961
17
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
18
Hydrochlorothiazide Approved, Vet_approved Phase 4,Early Phase 1 58-93-5 3639
19
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 1 144701-48-4 65999
20
Amlodipine Approved Phase 4,Phase 2,Phase 3,Early Phase 1 88150-42-9 2162
21
Atenolol Approved Phase 4,Early Phase 1 29122-68-7 2249
22
Chlorthalidone Approved Phase 4 77-36-1 2732
23
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
24
Piroxicam Approved, Investigational Phase 4 36322-90-4 5280452 54676228
25
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
26
Cilnidipine Approved Phase 4 132203-70-4 5282138
27
Macitentan Approved Phase 4,Phase 3 441798-33-0
28
Trichlormethiazide Approved, Vet_approved Phase 4 133-67-5 5560
29 Selexipag Approved Phase 4,Phase 3,Phase 2 475086-01-2
30
Coal tar Approved Phase 4 8007-45-2
31
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
32
Suvorexant Approved Phase 4 1030377-33-3
33
Warfarin Approved Phase 4 81-81-2 6691 54678486
34
Cilostazol Approved Phase 4 73963-72-1 2754
35
Acenocoumarol Approved Phase 4 152-72-7 9052 54676537
36
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
37
Angiotensin II Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68521-88-0, 11128-99-7 65143 172198
38 Tezosentan Phase 4,Phase 3,Phase 2
39 Sildenafil Citrate Phase 4,Phase 2,Phase 3,Phase 1 171599-83-0
40 Atorvastatin Calcium Phase 4,Phase 2,Phase 3 134523-03-8
41 Analgesics Phase 4,Phase 2,Phase 3,Early Phase 1
42 calcium channel blockers Phase 4,Phase 3,Phase 2,Phase 1
43 diuretics Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
44 Chelating Agents Phase 4,Phase 2,Phase 3
45 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Natriuretic Agents Phase 4,Phase 1,Phase 2,Early Phase 1
47 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Sodium Channel Blockers Phase 4,Phase 3,Phase 1
50 Adrenergic beta-1 Receptor Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 732)
id Name Status NCT ID Phase
1 Iron Deficiency In Pulmonary Hypertension Unknown status NCT01288651 Phase 4
2 Hemodynamic Response After Six Months of Sildenafil Unknown status NCT00483626 Phase 4
3 Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. Unknown status NCT00705588 Phase 4
4 Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost Unknown status NCT01649739 Phase 4
5 Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension Unknown status NCT01468571 Phase 4
6 Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease Unknown status NCT01383083 Phase 4
7 Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain Unknown status NCT01615627 Phase 4
8 Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan Unknown status NCT00625469 Phase 4
9 Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil Unknown status NCT00625079 Phase 4
10 A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis Unknown status NCT01042158 Phase 4
11 Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension Completed NCT01202175 Phase 4
12 STITCH2 (Simplified Therapeutic Intervention to Control Hypertension and Hypercholesterolemia) Completed NCT00637078 Phase 4
13 Bosentan in Treatment of Pulmonary Arterial Hypertension Completed NCT00266162 Phase 4
14 Interaction Between Antihypertensives and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Completed NCT00631514 Phase 4
15 Effect of Magnesium Administration in Subjects With Family History of Diabetes or Metabolic Syndrome Completed NCT01181830 Phase 4
16 Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401 Completed NCT01105117 Phase 4
17 Epoprostenol for Injection in Pulmonary Arterial Hypertension Completed NCT01105091 Phase 4
18 Comparison of Two Treatment Strategies in Hypertensive Patients Completed NCT00171444 Phase 4
19 An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH) Completed NCT01338636 Phase 4
20 Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1) Completed NCT00617305 Phase 4
21 TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) Completed NCT03055221 Phase 4
22 Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects Completed NCT00741819 Phase 4
23 Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) Completed NCT00303459 Phase 4
24 Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension Completed NCT00323297 Phase 4
25 Efficacy of Ventavis Used in Real-life Setting. Completed NCT01355380 Phase 4
26 Combination Therapy in Pulmonary Arterial Hypertension Completed NCT00433329 Phase 4
27 Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin) Completed NCT02074449 Phase 4
28 STITCH (Simplified Therapeutic Intervention To Control Hypertension) Completed NCT00129909 Phase 4
29 Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) Completed NCT02191137 Phase 4
30 Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension Completed NCT01330108 Phase 4
31 Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication Completed NCT01268553 Phase 4
32 Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH) Completed NCT00882947 Phase 4
33 Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) Completed NCT02847260 Phase 4
34 Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology Completed NCT00317486 Phase 4
35 Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH) Completed NCT01462565 Phase 4
36 BREATHE 5-OL: Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology Completed NCT00367770 Phase 4
37 A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension Completed NCT00058929 Phase 4
38 Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension Completed NCT00004754 Phase 4
39 Integrating Family Medicine and Pharmacy to Advance Primary Care Therapeutics Completed NCT00157638 Phase 4
40 Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension Completed NCT00403650 Phase 4
41 Pharmacogenomic Evaluation of Antihypertensive Responses Completed NCT00246519 Phase 4
42 Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults Completed NCT00439738 Phase 4
43 Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients Completed NCT01190007 Phase 4
44 PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM) Completed NCT00274638 Phase 4
45 Perioperative Cognitive Function - Dexmedetomidine and Cognitive Reserve Completed NCT00561678 Phase 4
46 The Effects of Cilnidipine on Metabolic Syndrome Improvement Completed NCT00325936 Phase 4
47 Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen Completed NCT00346216 Phase 4
48 Resistant Arterial Hypertension Cohort Study Recruiting NCT01083017 Phase 4
49 The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study Recruiting NCT02253394 Phase 4
50 Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA) Recruiting NCT02968901 Phase 4

Search NIH Clinical Center for Familial Hypertension

Genetic Tests for Familial Hypertension

Anatomical Context for Familial Hypertension

MalaCards organs/tissues related to Familial Hypertension:

39
Kidney

Publications for Familial Hypertension

Articles related to Familial Hypertension:

(show all 23)
id Title Authors Year
1
A PDE3A mutation in familial hypertension and brachydactyly syndrome. ( 27053290 )
2016
2
Characterisation of the Cullin-3 mutation that causes a severe form of familial hypertension and hyperkalaemia. ( 26286618 )
2015
3
The polymorphism of angiotensin-receptor gene A1166C in familial hypertension and its distribution in the Han Yellow race of China. ( 24145933 )
2013
4
An inducible transgenic mouse model for familial hypertension with hyperkalaemia (Gordon's syndrome or pseudohypoaldosteronism type II). ( 23336180 )
2013
5
Renal FMD may not confer a familial hypertensive risk nor is it caused by ACTA2 mutations. ( 21553326 )
2011
6
The metabolic syndrome and risk of myocardial infarction in familial hypertension (hypertension heredity in MalmAP evaluation study). ( 19050451 )
2009
7
The effects of exercise on haemodynamic function in relation to the familial hypertension risk model. ( 16496017 )
2006
8
Spironolactone responsive familial hypertension. A potentially high prevalence of mineralocorticoid disease in Oman. ( 12682699 )
2003
9
Influence of familial hypertension on blood pressure, serum cholesterol, high density lipoprotein cholesterol during second and third decade of life in Punjabi population. ( 15255633 )
2003
10
High urinary excretion of uric acid combined with high excretion of calcium links kidney stone disease to familial hypertension. ( 11812875 )
2002
11
Effect of familial hypertension on glomerular hemodynamics and tubulo-glomerular feedback after uninephrectomy. ( 11243302 )
2001
12
Abnormalities in insulin sensitivity, vascular resistance and erythrocyte cation transport are independent genetic traits in familial hypertension. ( 10451037 )
1999
13
Familial hypertension, insulin, sympathetic activity, and blood pressure elevation. ( 9674644 )
1998
14
Association of M235T variant of the angiotensinogen gene with familial hypertension of early onset. ( 7478115 )
1995
15
Familial hypertension and albuminuria in normotensive type I diabetic patients. ( 8282370 )
1994
16
Familial hypertension in Morgagni's De Sedibus et Causis Morborum per Anatomen Indagatis. ( 7847481 )
1994
17
Cross-sectional analysis of Met235-->Thr variant of angiotensinogen gene in severe, familial hypertension. ( 8267622 )
1993
18
Influence of familial hypertension of the donor on the blood pressure and antihypertensive therapy of kidney graft recipients. ( 7050749 )
1982
19
Influence of familial hypertension on blood pressure during adolescence. ( 6975038 )
1981
20
Familial hypertension and hormonal profile, renal haemodynamics and body fluids of young normotensive subjects. ( 282088 )
1978
21
Familial hypertension. ( 1185030 )
1975
22
Chronic hypertension following pre-eclamptic toxaemia: the influence of familial hypertension on its causation. ( 13564280 )
1958
23
Chronic hypertension following pre-eclamptic toxaemia; the influence of familial hypertension on its causation. ( 13367916 )
1956

Variations for Familial Hypertension

Expression for Familial Hypertension

Search GEO for disease gene expression data for Familial Hypertension.

Pathways for Familial Hypertension

Pathways related to Familial Hypertension according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.07 AGT AGTR1 PDE3A REN
2
Show member pathways
10.92 AGT AGTR1 CYP11B2 NR3C2 REN

GO Terms for Familial Hypertension

Cellular components related to Familial Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.83 AGT BMPR2 CAND1 COPS8 CUL3 GRK4
2 Cul3-RING ubiquitin ligase complex GO:0031463 9.33 CUL3 KLHL3 RBX1
3 cullin-RING ubiquitin ligase complex GO:0031461 8.8 CAND1 CUL3 RBX1

Biological processes related to Familial Hypertension according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of cell growth GO:0030308 9.82 AGT BMPR2 NPPA
2 kidney development GO:0001822 9.8 AGT AGTR1 REN
3 female pregnancy GO:0007565 9.79 AGT HSD11B2 NPPA
4 regulation of blood vessel size GO:0050880 9.64 AGT NPPA
5 positive regulation of cellular protein metabolic process GO:0032270 9.63 AGT AGTR1
6 post-translational protein modification GO:0043687 9.63 CAND1 COPS8 CUL3 KLHL3 RBX1 UBE2M
7 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.62 AGT AGTR1
8 low-density lipoprotein particle remodeling GO:0034374 9.61 AGT AGTR1
9 protein neddylation GO:0045116 9.6 RBX1 UBE2M
10 angiotensin maturation GO:0002003 9.59 AGT REN
11 positive regulation of cholesterol esterification GO:0010873 9.58 AGT AGTR1
12 positive regulation of cardiac muscle contraction GO:0060452 9.58 CHGA NPPA
13 cell growth involved in cardiac muscle cell development GO:0061049 9.57 AGT NPPA
14 negative regulation of systemic arterial blood pressure GO:0003085 9.56 BMPR2 NPPA
15 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.55 AGT AGTR1
16 SCF complex assembly GO:0010265 9.54 CAND1 RBX1
17 ion homeostasis GO:0050801 9.52 KLHL3 WNK4
18 positive regulation of NAD(P)H oxidase activity GO:0033864 9.51 AGT AGTR1
19 negative regulation of pancreatic juice secretion GO:0090188 9.49 WNK1 WNK4
20 regulation of renal sodium excretion GO:0035813 9.48 AGT AGTR1
21 renal sodium ion absorption GO:0070294 9.46 KLHL3 WNK4
22 regulation of blood volume by renin-angiotensin GO:0002016 9.43 AGT REN
23 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.4 AGT AGTR1
24 regulation of blood volume by renal aldosterone GO:0002017 9.37 CYP11B2 HSD11B2
25 distal tubule morphogenesis GO:0072156 9.32 KLHL3 WNK4
26 regulation of cellular process GO:0050794 9.26 WNK1 WNK4
27 regulation of blood pressure GO:0008217 9.26 AGT CHGA NPPA REN
28 renin-angiotensin regulation of aldosterone production GO:0002018 8.8 AGT AGTR1 REN
29 protein ubiquitination GO:0016567 10.03 CAND1 CUL3 KLHL3 RBX1 UBE2M

Molecular functions related to Familial Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 chloride channel inhibitor activity GO:0019869 8.96 WNK1 WNK4
2 NEDD8 transferase activity GO:0019788 8.62 RBX1 UBE2M

Sources for Familial Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....